

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-47. (cancelled)

48 (previously presented). A method for treating a congenital mitochondrial disease selected from the group consisting of Mitochondrial Encephalomyopathy, Lactic Acidemia, and stroke like episodes; Lerber's Hereditary Optic Neuropathy; Myclonic Epilepsy and "Ragged Red" (muscle) Fibers; Mitochondrial neurogastrointestinal encephalomyopathy; Neurogenic muscle weakness, Ataxia and Retinitis Pigmentosa; Progressive External Ophthalmoplegia; Leigh's Disease; and ~~Kearns-Sayres~~ Kearns-Sayres Syndrome in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

49 (previously presented). A method for treating Alzheimer's Disease in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

50 (previously presented). A method for treating Huntington's Disease in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

51 (previously presented). A method for treating a neuromuscular degenerative disease in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

52 (previously presented). A method as in claim 51 wherein said neuromuscular degenerative disease is selected from the group consisting of muscular dystrophy, myotonic dystrophy, chronic fatigue syndrome and Friedreich's Ataxia.

53 (previously presented). A method for treating pathophysiological consequences of mitochondrial respiratory chain dysfunction selected from the group consisting of developmental delay in cognitive, motor, language, executive function and social skills in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

54 (previously presented) A method for treating pathophysiological consequences of mitochondrial respiratory chain dysfunction selected from the group consisting of optic neuropathy, autonomic neuropathy, neurogenic bowel dysfunction, sensorineural deafness, neurogenic bladder dysfunction and migraine in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

55 (previously presented). A method for treating pathophysiological consequences of mitochondrial respiratory chain dysfunction selected from the group consisting of renal tubular acidosis, dilating cardiomyopathy and lactic acidemia in a mammal comprising administering to said mammal in need of such treatment an effective amount of a pyrimidine nucleotide precursor.

56 (previously presented). A method as in claim 53 wherein said developmental delay is pervasive developmental delay or pervasive developmental delay – not otherwise specified.

57 (previously presented). A method as in claim 53 wherein said developmental delay is Attention Deficit/Hyperactivity Disorder.

58 (previously presented). A method as in claim 53 wherein said developmental delay is Rett's Syndrome.

59 (previously presented). A method as in claim 53 wherein said developmental delay is autism.

60 (withdrawn). A method for reducing side effects of cytotoxic cancer chemotherapy agents by administering a pyrimidine nucleotide precursor, where said cytotoxic chemotherapy agent is not a pyrimidine nucleoside analog.

61 (withdrawn). A method as in claim 60 wherein said side effects of cytotoxic cancer chemotherapy are selected from the group consisting of peripheral neuropathy, chemotherapy-induced menopause, chemotherapy-associated fatigue and depressed appetite.

62 (previously presented). A method as in claim 48 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

63 (previously presented). A method as in claim 49 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

64 (previously presented). A method as in claim 50 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

65 (previously presented). A method as in claim 51 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

66 (previously presented). A method as in claim 53 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

VON BORSTEL

Appl. No. 09/763,955

April 22, 2003

67 (previously presented). A method as in claim 54 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

68 (previously presented). A method as in claim 55 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

69 (withdrawn). A method as in claim 60 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.